```html

Keratitis Sicca (Dry Eye Disease) – A Comprehensive Medical Guide

Overview

Keratitis sicca, commonly known as **dry eye disease (DED)**, is a chronic, multifactorial disorder of the ocular surface in which an inadequate quantity or quality of tears leads to **ocular irritation, visual disturbance, and potential damage to the cornea and conjunctiva**.

• Who it affects: Adults of any age, but prevalence rises sharply after age 40. Women are up to twice as likely as men to develop DED, especially post‑menopausal women.
• Prevalence: Approximately 5–30 % of the global population experiences clinically significant dry eye, with higher rates in Asian countries (up to 33 %) and among contact‑lens wearers.<sup>[1] Mayo Clinic</sup>
• Impact: The disease is a leading cause of ocular discomfort and reduces quality of life comparable to chronic musculoskeletal pain.<sup>[2] WHO</sup>

Symptoms

Symptoms can be intermittent or continuous and often worsen in certain environments (wind, air conditioning, screen use). Common presentations include:

• Foreign‑body sensation – feeling of grit or sand in the eye.
• Burning, stinging, or itching.
• Redness (hyperemia) of the conjunctiva.
• Blurred or fluctuating vision, especially after prolonged reading or computer use.
• Excessive tearing (reflex tearing) – paradoxical response to irritation.
• Light sensitivity (photophobia).
• Difficulty wearing contact lenses.
• Sticky or stringy discharge.
• Eye fatigue or heaviness.

Symptoms often follow the “**Ocular Surface Disease Index (OSDI)**” scoring system, a validated questionnaire used by clinicians to quantify severity.<sup>[3] NIH</sup>

Causes and Risk Factors

Dry eye disease results from an **imbalance** between tear production, tear evaporation, and tear film stability. The main categories are:

1. Aqueous‑deficient dry eye

• Reduced tear secretion from the lacrimal glands (e.g., Sjögren’s syndrome, rheumatoid arthritis, lupus).
• Medication‑induced suppression (antihistamines, antidepressants, beta‑blockers, isotretinoin).
• Age‑related decline in gland function.

2. Evaporative dry eye

• Meibomian gland dysfunction (MGD) – altered lipid secretion leads to rapid tear evaporation.
• Environmental factors: low humidity, wind, smoke, air‑conditioned rooms.
• Excessive screen time, which reduces blink rate.

3. Combined forms

Many patients have overlapping aqueous deficiency and evaporative components.

Risk Factors

• Female sex, especially post‑menopausal.
• Age > 40 years.
• Autoimmune diseases (Sjögren’s, rheumatoid arthritis, thyroid disease).
• Contact‑lens wear, particularly extended‑wear lenses.
• Refractive or cataract surgery (temporary disruption of corneal nerves).
• Systemic medications that decrease tear production.
• Digital device use ≥ 2 hours/day (reduced blink rate ≈ 30 %).
• Environmental exposures – “dry office,” high altitude, or pollution.

Diagnosis

Diagnosis combines patient history, symptom questionnaires, and objective clinical tests.

History & Symptom Assessment

• OSDI or DEQ‑5 questionnaire.
• Medication review and systemic disease screening.

Clinical Examination

• Slit‑lamp biomicroscopy – evaluates lid margin, meibomian glands, corneal staining.
• Fluorescein or Lissamine Green staining – highlights epithelial damage; graded by the Oxford or NEI scale.
• Tear Break‑Up Time (TBUT) – time for first dry spot after a blink; <10 seconds is abnormal.
• Schirmer test (with or without anesthesia) – measures aqueous tear production; ≤5 mm in 5 min suggests aqueous deficiency.
• Meibography – infrared imaging of meibomian gland architecture; used for MGD assessment.
• Osmolarity testing – tear osmolarity > 308 mOsm/L supports DED diagnosis (device: TearLab).

Laboratory Work‑up (if autoimmune involvement suspected)

• ANA, rheumatoid factor, anti‑SSA/SSB antibodies.

Treatment Options

Treatment aims to **restore tear film stability**, reduce inflammation, and protect the ocular surface. Management is usually stepped, beginning with the least invasive measures.

1. Lifestyle & Environmental Modifications

• Increase ambient humidity (humidifiers).
• Take “20‑20‑20” breaks during screen work (every 20 min, look at 20 ft for 20 sec).
• Consciously blink every few seconds.
• Avoid direct airflow from fans, car vents, or air‑conditioners.
• Wear wrap‑around glasses in windy conditions.

2. Artificial Tears (Lubricants)

• Preservative‑free drops are preferred for frequent use.
• Viscosity options:
  • Low viscosity – comfortable for blinking, good for mild disease.
  • High viscosity (e.g., carboxymethylcellulose, hyaluronic acid) – forms a protective film, useful at night.
• Typical dosing: 1–2 drops per eye, 4–6 times daily; increase as needed.

3. Anti‑Inflammatory Therapies

• Cyclosporine A 0.05 % ophthalmic solution (Restasis) – reduces T‑cell mediated inflammation; onset 4–6 weeks.
• Lifitegrast 5 % (Xiidra) – blocks LFA‑1/ICAM‑1 interaction; improves symptoms within 2 weeks.
• Short‑course topical corticosteroids (e.g., prednisolone acetate) for acute flare‑ups, usually ≤2 weeks under supervision.

4. Meibomian Gland Therapy

• Warm compresses (5–10 minutes) followed by gentle lid massage.
• In‑office **LipiFlow** or **Thermal pulsation** devices to unblock glands.
• Topical azithromycin eye drops (off‑label) for their anti‑inflammatory effect on MGD.

5. Punctal Occlusion

• Temporary silicone plugs (e.g., SmartPlug) inserted into lacrimal puncta to retain tears.
• Permanent occlusion (cryotherapy or cautery) for refractory cases.

6. Advanced or Procedural Options

• Autologous serum eye drops – contain growth factors; used for severe ocular surface disease.
• Amniotic membrane transplantation** – for persistent epithelial defects.
• Intense pulsed light (IPL) – targets abnormal vessels and improves meibomian function.

7. Systemic Therapy (when underlying autoimmune disease is present)

• Hydroxychloroquine for Sjögren’s syndrome.
• Systemic doxycycline (low dose) for its anti‑matrix‑metalloproteinase effect on meibomian glands.

Living with Keratitis sicca (dry eye disease)

Effective self‑management reduces discomfort and prevents complications.

• Hydration: Drink 8‑10 glasses of water daily; dehydration worsens tear osmolarity.
• Nutrition: Omega‑3 fatty acids (fish oil, flaxseed) 1–2 g/day have modest benefit.<sup>[4] Cleveland Clinic</sup>
• Protective eyewear: Sunglasses with side shields reduce evaporative loss.
• Contact lens care: Use daily‑disposable lenses or limit wear time; replace lenses as scheduled.
• Sleep hygiene: Ensure eyelids close fully; consider night‑time lubricating ointment.
• Medication review: Discuss any systemic drug that may cause dry eye with your clinician.
• Regular follow‑up: At least once every 6‑12 months, or sooner if symptoms change.

Prevention

While some risk factors (age, genetics) are non‑modifiable, many preventive steps can lower the likelihood of developing DED or mitigate its severity.

• Limit exposure to smoke and pollutants.
• Use humidifiers in dry indoor environments.
• Adopt proper ergonomics: screen at eye level, 20‑inch distance.
• Avoid over‑use of preservative‑containing eye drops; prefer preservative‑free formulations.
• Schedule periodic eye exams, especially before starting systemic medications known to reduce tear production.
• Maintain lid hygiene – gentle cleaning with commercially available lid scrubs or diluted baby shampoo.

Complications

If left untreated, chronic keratitis sicca can lead to serious ocular morbidity.

• Corneal epithelial breakdown – persistent staining, ulceration, and risk of infection.
• Filamentary keratitis – mucus strands adhere to the cornea causing pain.
• Scarring and neovascularization – may impair visual acuity.
• Increased susceptibility to bacterial, viral, or fungal keratitis.
• Contact lens intolerance – limiting visual correction options.
• Reduced quality of life – chronic pain, difficulty reading or driving, especially at night.

When to Seek Emergency Care

Urgent warning signs that require immediate evaluation by an eye‑care professional or emergency department:

• Sudden onset of severe pain or a feeling that something is “stuck” in the eye.
• Rapid vision loss, flashes of light, or new “black spots.”
• Marked redness accompanied by discharge that is yellow/green (possible infection).
• Sensitivity to light with intense photophobia.
• Corneal ulcer or a white spot on the cornea seen on exam.
• History of recent eye surgery or trauma with worsening symptoms.

If any of these occur, seek care promptly to prevent permanent damage.

---

References (selected):

1. Mayo Clinic. “Dry eye.” Updated 2023. https://www.mayoclinic.org/dry-eye
2. World Health Organization. “Global prevalence of dry eye disease.” 2022.
3. National Institutes of Health, National Eye Institute. “Ocular Surface Disease Index (OSDI).” 2021.
4. Cleveland Clinic. “Omega‑3 Fatty Acids for Dry Eye.” 2024.
5. American Academy of Ophthalmology. “Dry Eye Disease Preferred Practice Pattern.” 2022.

```